Canada: a haven for generic drugs?
Medical News Today reports that Canada is proposing to amend its patent law in order to optimize the balance between encouraging continued innovation in new drugs and promoting timely generic competition. Under the proposal pharmaceutical companies will not be able to extend the period of data exclusivity that they are granted in a way that is incompatible with the original purpose of such protection. This should enable generics to come to the market more easily. However, for genuinely innovative drugs, the data exclusivity period will be extended from 6 years to 8 years, with an extra 6 months for drugs which have been the subject of clinical trials on children.
The IPKat welcomes this subtle approach, which directs its measures specifically to the problems identified, rather than a “one size fits all” approach.
More on generic drugs in Canada here, here and here
Canada-related Monty Python sketch here
CANADA PROPOSES GENERIC DRUGS PATENT AMENDMENT
![CANADA PROPOSES GENERIC DRUGS PATENT AMENDMENT]()
Reviewed by Anonymous
on
Wednesday, December 22, 2004
Rating:
Follow the IPKat on LinkedIn 
![[Guest post] Asking ourselves ‘Y’ – Are shape marks shaping complex products’ aftermarkets?](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhHwE0es_m0lzJpedp0KFtKOYBne_M3YPJ-qwQxiY_YMkHffLAAXkSW9F-pjQFKsy5kJJ-VWScQQkuEVb5-BxnDv10XIMAbYhvgzBSQadD1gdTiIjg9-Oj9Iekll-C3Ca9I76uI3Hh5nCI4QyLosLSNev9VzLq9lF1jM86ungheEDOBKLzGTbE3yw/s72-c/Picture%201.png)
![[Guest post] Flat rates supported by clauses on universality of repertoire in contracts between CMOs and users are anti-competitive, says Spanish Competition Authority](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhpBg7o3d7DPzH4YqNz3DUV5J5_sS4P7X7ZznFNETyQlLe0gonaSi3eE_jdjHD_aIjbPKhgpvUrkg6tPprYQYdwDGiyuWIXty9BOUlc07wUVbjDxI1bHoVxZA0ZCC9HBPjLXQwUioBSd9e9n-Z3uCeJ9UUgEvtJHLo1AllR20HGJETFdKoovxLBMw/s72-c/images.png)
![[Guest post] Thou shalt not discriminate the Lego block over any other kind of product – GRUR speaks out on C-211/24](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgWJYQUJNvYydrZcjwSHPuxd14xX3_48aBusHKBogY-Wg1BPSJSABbFFjmGiUV3aqG2npP9xYaIl1vtWK5AsqGOQPgRD2TWFLhyyc4xGm1fHDD-tt9kHcrSSgAyju2P9wSKz0VW6h7D5MD4Hxd9vREyxKYzlMRNXxxtxc3DiNsXppfVaxgSxAMV/s72-c/21742619125_7c9e53cd39_o.png)
Posts
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html